Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of the American College of Cardiology

• Publication date

  2014-04-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jacc.2014.01.006PMID 24509273
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.

  2014cited by this paper
• When should we measure lipoprotein (a)?

  2013cited by this paper
• Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor: Evidence for a Reciprocal Regulation

  2013cited by this paper
• Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?

  2013cited by this paper
• Insights into PCSK9, LDL Receptor and LDL Cholesterol Metabolism: Of Mice and Man

  2013cited by this paper
• Insights into PCSK9, low-density lipoprotein receptor, and low-density lipoprotein cholesterol metabolism: of mice and man.

  2013cited by this paper
• HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

  2013cited by this paper
• Emerging therapeutic agents to lower lipoprotein (a) levels

  2012cited by this paper
• Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

  2012cited by this paper
• Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

  2012cited by this paper
• Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study.

  2012cited by this paper
• Proprotein Convertase Subtilisin/Kexin Type 9 Interacts With Apolipoprotein B and Prevents Its Intracellular Degradation, Irrespective of the Low-Density Lipoprotein Receptor

  2012cited by this paper
• Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterole

  2012cited by this paper
• Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.

  2012cited by this paper
• Antisense therapy in the treatment of hypercholesterolemia.

  2011cited by this paper
• Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

  2011cited by this paper
• Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia.

  2010cited by this paper
• Lipoprotein(a) as a cardiovascular risk factor: current status

  2010cited by this paper
• Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.

  2009cited by this paper
• Genetic variants associated with Lp(a) lipoprotein level and coronary disease.

  2009cited by this paper
• Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.

  2009cited by this paper
• Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data.

  2008cited by this paper
• Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia.

  2005cited by this paper
• Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity

  2004cited by this paper
• First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay – Lp(a) SRM 2B

  2004cited by this paper
• High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial

  2004cited by this paper
• Lipoprotein(a) in homozygous familial hypercholesterolemia.

  2000cited by this paper
• The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans.

  1995cited by this paper
• The Recurring Evolution of Lipoprotein(a)

  1995cited by this paper
• Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100.

  1993cited by this paper
• Abetalipoproteinemia with an ApoB-100-lipoprotein(a) glycoprotein complex in plasma. Indication for an assembly defect.

  1990cited by this paper
• Lipoprotein (a). Heterogeneity and biological relevance.

  1990cited by this paper
• HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels.

  1989cited by this paper
• The mysteries of lipoprotein(a).

  1989cited by this paper

• Management of dyslipidemia in adults. A consensus statement from the French Society of Endocrinology (SFE), the French-speaking Diabetes Society (SFD), the New French-speaking Atherosclerosis Society (NSFA) and the French Society of Cardiology (SFC).

  2026cites this paper
• Management of dyslipidemia in adults. A consensus statement from the French Society of Endocrinology (SFE), the French-speaking Diabetes Society (SFD), the New French-speaking Atherosclerosis Society (NSFA) and the French Society of Cardiology (SFC).

  2026cites this paper
• Overview of the Study of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease

  2026cites this paper
• Relationship between lipoprotein(a) and PCSK9 in angiogram-proven premature coronary artery disease in an Asian cohort

  2026cites this paper
• Elevated lipoprotein(a) and its association with early-onset myocardial infarction and coronary burden

  2025cites this paper
• Coronary Artery Calcium Scoring in the Context of Widespread Lipoprotein(a) Testing: Clinical Considerations and Implications for Lipid-Lowering Therapies

  2025cites this paper
• Optimizing PCSK9 inhibitor therapy: Understanding and managing suboptimal LDL-C response in clinical practice.

  2025cites this paper
• Efficacy and safety of ongericimab in patients with dyslipidemia: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials.

  2025cites this paper
• Optimal Medical Therapy Targeting Lipids and Inflammation for Secondary Prevention in Patients Undergoing Percutaneous Coronary Intervention

  2025cites this paper
• Barriers and strategies in detection and management of elevated Lipoprotein(a) in hospital: A pre-implementation qualitative study of cardiology healthcare professionals

  2025cites this paper
• Lipoprotein(a) as a multisystem disease risk factor: Clinical implications and the Dawn of RNA-based therapeutics.

  2025cites this paper
• Inadequate Response to PCSK9 Inhibitors

  2025cites this paper
• Efficacy and safety of evolocumab in statin-treated patients with cardiovascular risk factors: a systematic review and meta-analysis

  2025cites this paper
• Role of CETP, PCSK-9, and CYP7-alpha in cholesterol metabolism: Potential targets for natural products in managing hypercholesterolemia.

  2024cites this paper
• Lipoprotein (a) testing patterns among subjects with a measured lipid panel: The Mayo Clinic experience

  2024cites this paper
• Weekly journal scan: a new small-interfering RNA to fight a genetic cardiovascular risk factor.

  2024cites this paper
• Lipoprotein(a) in Children and Adolescents: Risk or Causal Factor for Cardiovascular Disease? A Narrative Review

  2024cites this paper
• Espoirs et place prochaine potentielle des inhibiteurs de la Lp(a)

  2024cites this paper
• Progress in pediatric cardiology VSI: Cardiovascular disease in pediatrics lipoprotein(a) in atherosclerotic cardiovascular disease, type 2 diabetes, and liver disease

  2024cites this paper
• Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases

  2024cites this paper
• Lipoprotein(a): Are we ready for large-scale clinical trials?

  2024cites this paper
• A comprehensive retrospect on biomarkers indicating vascular failure

  2024cites this paper
• Lipoprotein(a) in patients with breast cancer after chemotherapy: exploring potential strategies for cardioprotection

  2023cites this paper
• Novel and future lipid-modulating therapies for the prevention of cardiovascular disease

  2023cites this paper
• Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans

  2023cites this paper
• Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies

  2023influential citation
• Lp(a) and inflammation: a new insight into atherosclerosis

  2023cites this paper
• Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial

  2023cites this paper
• Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a)

  2023cites this paper
• PCSK9 inhibition in atherosclerotic cardiovascular disease.

  2023cites this paper
• Daring to Dream: Targeting Lipoprotein(a) as a Causal and Risk-Enhancing Factor.

  2023cites this paper
• Gene transfer and genome editing for familial hypercholesterolemia

  2023cites this paper
• Therapeutic Apheresis and Human Monoclonal Antibodies in Non-Immunologic Diseases.

  2023cites this paper
• Surface LDLR is a major receptor for lipoprotein(a) clearance in male mice lacking PCSK9.

  2023cites this paper
• Genetics of aortic valve disease

  2023cites this paper
• Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels—Potent Clinical Implications

  2023cites this paper
• Lipoprotein(a) in clinical practice: A guide for the clinician.

  2023cites this paper
• The evolving landscape of PCSK9 inhibition in cancer.

  2023cites this paper
• Genetic and molecular architecture of familial hypercholesterolemia

  2022cites this paper
• Clinical associations between exercise and lipoproteins

  2022cites this paper
• Lipid-Lowering Therapy in Women of Childbearing Age: a Review and Stepwise Clinical Approach

  2022cites this paper
• Lipoprotein(a)—When to Screen and How to Treat

  2022cites this paper
• Lipoprotein(a)

  2022cites this paper
• Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.

  2022cites this paper
• Elevated Lipoprotein(a) as a potential residual risk factor associated with lipid-rich coronary atheroma in patients with type 2 diabetes and coronary artery disease on statin treatment: Insights from the REASSURE-NIRS registry.

  2022cites this paper
• Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target

  2022cites this paper
• Role of Lipoprotein(a) in Cardiovascular Disease: A Review of Clinical Practice

  2022cites this paper
• Value of repeated measurements of lipoprotein (a) to assess cardiovascular risk: a retrospective study

  2022cites this paper
• Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia.

  2022cites this paper
• Therapeutic RNA-silencing oligonucleotides in metabolic diseases

  2022cites this paper
• Lipoprotein(a): An underestimated inflammatory mastermind.

  2022cites this paper
• Apo(a) and ApoB Interact Noncovalently Within Hepatocytes: Implications for Regulation of Lp(a) Levels by Modulation of ApoB Secretion

  2022cites this paper
• Pharmacotherapy for children with elevated levels of lipoprotein(a): future directions

  2022cites this paper
• The associations between exercise and lipid biomarkers.

  2022cites this paper
• PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center

  2022cites this paper
• Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option

  2022cites this paper
• Approaches to Visualising Endocytosis of LDL-Related Lipoproteins

  2022cites this paper
• Lipoprotein(a) and Cardiovascular Disease in Chinese Population

  2022cites this paper
• Mendelian randomization

  2022cites this paper
• Lipoprotein (a): When to Measure and How to Treat?

  2021cites this paper
• Don't we forget about biological therapy of hypercholesterolemia with PCSK9-inhibitors?

  2021cites this paper
• Risk stratification of ST-segment elevation myocardial infarction (STEMI) patients using machine learning based on lipid profiles

  2021cites this paper
• Cardiovascular Risk Assessment in the Older Athlete

  2021cites this paper
• Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy.

  2021cites this paper
• Cardiovascular events in patients with familial hypercholesterolemia and hyperlipoproteinaemia (a): Indications for lipoprotein apheresis in Poland

  2021cites this paper
• Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases

  2021cites this paper
• Relations of physical signs to genotype, lipid and inflammatory markers, coronary stenosis or calcification, and outcomes in patients with heterozygous familial hypercholesterolemia

  2021cites this paper
• Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update.

  2021cites this paper
• Novel therapeutic targets and agents for pediatric dyslipidemia

  2021cites this paper
• Precision medicine in secondary prevention of ischemic stroke: how may blood-based biomarkers help in clinical routine? An expert opinion

  2021cites this paper
• Lipid Metabolism, Disorders and Therapeutic Drugs – Review

  2021cites this paper
• Lipoprotein(a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and/or Residual Risk

  2021cites this paper
• Impact of lipoprotein(a) level on cardiometabolic disease in the Chinese population: The CHCN‐BTH Study

  2021cites this paper
• Coronary Artery Disease: Optimal Lipoprotein(a) for Survival—Lower Is Better? A Large Cohort With 43,647 Patients

  2021cites this paper
• Case Report: Difficulties in the Treatment of a 12-Year-Old Patient With Homozygous Familial Hypercholesterolemia, Compound Heterozygous Form − 5 Years Follow-Up

  2021cites this paper
• Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Société Francophone d'Athérosclérose (NSFA).

  2021cites this paper
• Dyslipidaemias and cardiovascular disease: Focus on the role of PCSK9 inhibitors Olga Panagiotopoulou.

  2020cites this paper
• Genetic Disorders of Lipoprotein Metabolism

  2020cites this paper
• Elevated levels of serum PCSK9 in male patients with symptomatic peripheral artery disease: The CAVASIC study.

  2020cites this paper
• Familial Hypercholesterolaemia: An Updated Overall Management

  2020cites this paper
• Lipoprotein(a) reduction with proprotein convertase subtilisin/kexin type 9 inhibitors: a systematic review and meta-analysis.

  2020cites this paper
• Evolocumab improves intima media thickness regression in HeFH subjects on lipoprotein apheresis.

  2020cites this paper
• Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects

  2020cites this paper
• Inhibiteurs PCSK9 en pratique clinique : données et interrogations

  2020cites this paper
• «The role of Lipoprotein(a) in cardiovascular disease; Current concepts and future perspectives».

  2020cites this paper
• Relationship between Lipoprotein (a) and cognitive function – Results from the Berlin Aging Study II

  2020cites this paper
• Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach

  2020cites this paper
• Biotechnology Approaches for the Treatment of Dyslipidemia

  2020cites this paper
• Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options

  2020cites this paper
• Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hypercholesterolemia.

  2020cites this paper
• Lipid lowering therapy in cardiovascular disease: From myth to molecular reality.

  2020cites this paper
• Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations.

  2020cites this paper
• Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)

  2020cites this paper
• Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study

  2020cites this paper
• Plasma kinetics of mature PCSK9, furin-cleaved PCSK9, and Lp(a) with or without administration of PCSK9 inhibitors in acute myocardial infarction.

  2020cites this paper
• Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies.

  2020cites this paper
• Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies.

  2020cites this paper
• Lipidsenkende Therapie zur Sekundärprävention der peripheren arteriellen Verschlusskrankheit

  2020cites this paper
• Impact of serum lipoprotein (a) level on coronary plaque progression and cardiovascular events in statin-treated patients with acute coronary syndrome: a yokohama-acs substudy.

  2020cites this paper
• Lipoprotein removal mechanisms and aging: implications for the cardiovascular health of the elderly.

  2020cites this paper